Journal of Cancer Policy最新文献

{"title":"A novel ensemble framework for comprehensive early-stage colorectal cancer diagnosis, prognosis, and treatment: Integration of gastroenterology-specific transformer language models and multiple decision trees","authors":"Cem Simsek , Suayib Yalcin , Mete Ucdal , Derya Karakoc","doi":"10.1016/j.jcpo.2024.100535","DOIUrl":"10.1016/j.jcpo.2024.100535","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100535"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Language as a barrier to colorectal cancer screening in Flanders: An ecological study","authors":"S.M. Van den bergh , L. Casas , G. Ertaylan , G. Van Hal , J. Bessems","doi":"10.1016/j.jcpo.2024.100538","DOIUrl":"10.1016/j.jcpo.2024.100538","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100538"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer care in humanitarian crises: The role of global nursing organisations","authors":"M. Ibrahim , R. Hollis , E. McFerran","doi":"10.1016/j.jcpo.2024.100539","DOIUrl":"10.1016/j.jcpo.2024.100539","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100539"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Belgian Cancer Inventory: Co-creating a framework for monitoring the implementation of cancer policies and associated inequalities","authors":"Robbe Saesen , Gabrielle Schittecatte , Jinane Ghattas , Marie Delnord","doi":"10.1016/j.jcpo.2024.100549","DOIUrl":"10.1016/j.jcpo.2024.100549","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100549"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of digital cognitive-behavioral therapy for insomnia in cancer survivors: The OncoSleep randomized controlled trial","authors":"Maria Inês Clara , Josephine Hegarty , Annemieke Van Straten , Maria Cristina Canavarro , Ana Allen Gomes","doi":"10.1016/j.jcpo.2024.100536","DOIUrl":"10.1016/j.jcpo.2024.100536","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100536"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Cancer research funding in South Asia” [J. Cancer Policy 41 (2024) 100489]","authors":"Sehar Salim Virani , Kaleem Sohail Ahmed , Taylor Jaraczewski , Syed Nabeel Zafar","doi":"10.1016/j.jcpo.2024.100523","DOIUrl":"10.1016/j.jcpo.2024.100523","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100523"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes from a virtual clinic developed to manage gastrointestional consequences of colorectal cancer","authors":"Darren Fernandes , H. Jervoise N. Andreyev","doi":"10.1016/j.jcpo.2024.100540","DOIUrl":"10.1016/j.jcpo.2024.100540","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100540"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer driven direct medical costs in Bangladesh: Evidence from patient perspective","authors":"Md. Shahjalal ,&nbsp;Md. Parvez Mosharaf ,&nbsp;Padam Kanta Dahal ,&nbsp;Mohammad Enamul Hoque ,&nbsp;Rashidul Alam Mahumud","doi":"10.1016/j.jcpo.2025.100565","DOIUrl":"10.1016/j.jcpo.2025.100565","url":null,"abstract":"<div><h3>Background</h3><div>Cancer treatment costs are rising, and the disease is becoming a major challenge to healthcare systems in developing countries like Bangladesh. The direct medical costs of cancer have yet to be comprehensively studied in the country. Hence, the study aimed to estimate the direct medical costs associated with cancer from patients’ perspective.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted in two tertiary specialised cancer hospitals. Data on direct medical costs incurred during treatment in the last three months were collected. The average per-patient costs for cancer treatment were computed and stratified by cancer sites, stages, and types of health facilities. A generalised linear model was used to test the mean cost difference in healthcare services by cancer sites, stages, and type of health facility.</div></div><div><h3>Results</h3><div>Overall, the per-patient direct medical costs were BDT 41,019 (US$477), with 33 % allocated to hospitalisation (BDT 13,420; $156) followed by 29 % for surgery (BDT 11,833; $138). Patients with gallbladder (BDT 94,722; $1101), brain (BDT 82,608; $961), and esophageal cancer (BDT 82,556; $960) had the highest average treatment costs. The mean costs per patient were BDT 42,050 ($489), BDT 40,583 ($472), BDT 40,892 ($475), BDT 38,252 ($445) and BDT 53,306 ($620) for disease stages 0, I, II, III, and IV, respectively. The costs increased by 0.63 % from stage I to II but decreased by 7 % from stage II to III while rising sharply by 39 % from stage III to IV. The costs for patients with gallbladder, pancreatic and brain cancer were significantly higher at BDT 51,194 ($595), BDT 43,637 ($507) and BDT 39,338 ($457) compared to patients with oral cancer, respectively. On average, per-patient costs were 5 % higher in private health facility (BDT 42,947; $499) compared to public hospital (BDT 40,743; $474).</div></div><div><h3>Conclusion</h3><div>This study reveals that cancer treatment costs are high in advanced stages and in private hospital. The findings suggest that earlier diagnosis and financial subsidies may help curb the ongoing high cancer treatment costs.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100565"},"PeriodicalIF":2.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation challenges of government-funded health schemes for cancer treatment at Tata Memorial Centre","authors":"Suvarna Gore ,&nbsp;Sharyu Mhamane ,&nbsp;Sunita Jadhav ,&nbsp;Narpat Padvi ,&nbsp;Amruta Mhatre ,&nbsp;Prachi Joshi ,&nbsp;Sandeep Sawakare ,&nbsp;Vinit Samant ,&nbsp;Pankaj Chaturvedi ,&nbsp;C.S. Pramesh ,&nbsp;Sudeep Gupta ,&nbsp;Atul Budukh","doi":"10.1016/j.jcpo.2025.100564","DOIUrl":"10.1016/j.jcpo.2025.100564","url":null,"abstract":"<div><h3>Background</h3><div>The study aims to understand the Ayushman Bharat- Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) and Mahatma Jyotirao Phule Jan Arogya Yojana (MJPJAY)health scheme awareness, challenges faced by the scheme beneficiaries, facilitators and out-of-pocket expenditure (OOPE) for cancer treatment at Tata Memorial Hospital, Mumbai.</div></div><div><h3>Methods</h3><div>We conducted an observational cross-sectional study approved by the Tata Memorial Centre Ethics Committee. We collected data by interviewing participants through a structured questionnaire.</div></div><div><h3>Results</h3><div>Out of 515 participants, 489 (95 %) were beneficiaries (patients/caregivers) of the schemes, 15 (2.9 %) MJPJAY staff, 6 (1.1 %) medical social workers (MSW), and 5 (1.0 %) AB PM-JAY staff. Of the 489 beneficiaries, only 162 (33.1 %) were aware of the scheme. Most patients were satisfied with the benefits of the scheme; of the 83 (17 %) who were dissatisfied, 30 (36 %) cited incomplete coverage at a 95 % Confidence Interval (CI) [0.26–0.46] and 19 (23 %) 95 % CI [0.14–0.32] cited OOPE as the reason for dissatisfaction. Participants opined a need to increase package coverage of cancer treatment and essential investigations. The beneficiaries highlighted delays in the approval process and technical issues of the scheme as potential areas of improvement.</div></div><div><h3>Conclusion</h3><div>Government health schemes are effective in improving treatment completion without impoverishment and have the potential to improve treatment outcomes and cancer survival. Study results indicate the need to increase awareness about these schemes in the general population, improving the health benefit packages for cancer treatment, with inclusion investigations, supportive care, nutritional care, palliative care, immunotherapy, chemotherapy drugs, targeted therapy, bone marrow transplantation, and hormonal therapy.</div></div><div><h3>Policy summary</h3><div>Government-funded health schemes are effective in reducing impoverishment related to healthcare costs and promoting Universal Health Coverage. However, periodic review of the breadth of coverage as well as feasibility of completing treatment using these packages is necessary to eliminate out-of-pocket expenditure and facilitate treatment completion.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100564"},"PeriodicalIF":2.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating EU clinical trials: Adapting to a new era of regulations","authors":"Stéphanie Kromar ,&nbsp;Rana Kassas","doi":"10.1016/j.jcpo.2025.100563","DOIUrl":"10.1016/j.jcpo.2025.100563","url":null,"abstract":"<div><div>In recent years, new healthcare regulations have been introduced in the aim of standardising implementation processes across European Union (EU) member states, while maintaining high ethical and scientific standards for healthcare innovation. In clinical research, the simultaneous application of multiple EU regulations to clinical trials poses significant challenges. The interplay between these regulations’ requirements is explored. These regulations often overlap in scope but differ in requirements, creating compliance complexities for healthcare stakeholders in general, and for sponsors of clinical trials in particular. Clinical research programs aimed at optimising treatment for patients may struggle under the new regulatory environment that poses additional administrative and financial burdens, despite their potential benefits for patients and healthcare systems. Addressing these challenges is crucial to ensuring that clinical trials can safely and effectively integrate technological advancements into healthcare systems, ultimately benefiting patients and healthcare providers alike. Coordinated efforts to navigate differing workflows for trials involving both drugs and devices are being addressed at a pan-European level. Today, the European Organisation for the Research and Treatment of Cancer (EORTC) is involved in two high-level initiatives led by the Commission aimed at tackling the challenges in cancer research.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100563"},"PeriodicalIF":2.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}